Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
Alghamri MS, Banerjee K, Mujeeb AA, Mauser A, Taher A, Thalla R, McClellan BL, Varela ML, Stamatovic SM, Martinez-Revollar G, Andjelkovic AV, Gregory JV, Kadiyala P, Calinescu A, Jiménez JA, Apfelbaum AA, Lawlor ER, Carney S, Comba A, Faisal SM, Barissi M, Edwards MB, Appelman H, Sun Y, Gan J, Ackermann R, Schwendeman A, Candolfi M, Olin MR, Lahann J, Lowenstein PR, Castro MG. Alghamri MS, et al. Among authors: olin mr. ACS Nano. 2022 Jun 28;16(6):8729-8750. doi: 10.1021/acsnano.1c07492. Epub 2022 May 26. ACS Nano. 2022. PMID: 35616289 Free PMC article.
Correction to: CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway.
Ampudia-Mesias E, Puerta-Martinez F, Bridges M, Zellmer D, Janeiro A, Strokes M, Sham YY, Taher A, Castro MG, Moertel CL, Pluhar GE, Olin MR. Ampudia-Mesias E, et al. Among authors: olin mr. Neurotherapeutics. 2021 Jul;18(3):2131. doi: 10.1007/s13311-021-01062-1. Neurotherapeutics. 2021. PMID: 33929711 Free PMC article. No abstract available.
Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.
Alghamri MS, McClellan BL, Hartlage CS, Haase S, Faisal SM, Thalla R, Dabaja A, Banerjee K, Carney SV, Mujeeb AA, Olin MR, Moon JJ, Schwendeman A, Lowenstein PR, Castro MG. Alghamri MS, et al. Among authors: olin mr. Front Pharmacol. 2021 May 18;12:680021. doi: 10.3389/fphar.2021.680021. eCollection 2021. Front Pharmacol. 2021. PMID: 34084145 Free PMC article. Review.
Comparison of peripheral leukocyte parameters in patients receiving conventionally and hypofractionated radiotherapy schemes for the treatment of newly diagnosed glioblastoma.
Greenlund L, Shanley R, Mulford K, Neil EC, Lawrence J, Arnold S, Olin M, Pluhar GE, Venteicher AS, Chen CC, Ferreira C, Reynolds M, Cho LC, Wilke C, Shoo BA, Yuan J, Dusenbery K, Kleinberg LR, Terezakis SA, Sloan L. Greenlund L, et al. Front Immunol. 2023 Oct 26;14:1284118. doi: 10.3389/fimmu.2023.1284118. eCollection 2023. Front Immunol. 2023. PMID: 38022656 Free PMC article.
CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy.
Xiong Z, Ampudia Mesias E, Pluhar GE, Rathe SK, Largaespada DA, Sham YY, Moertel CL, Olin MR. Xiong Z, et al. Among authors: olin mr. Clin Cancer Res. 2020 Jan 1;26(1):232-241. doi: 10.1158/1078-0432.CCR-19-2234. Epub 2019 Oct 17. Clin Cancer Res. 2020. PMID: 31624103
46 results